Sanofi - Company Profile
Powered by 
All the sales intelligence you need on Sanofi in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Sanofi fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Sanofi.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreSanofi is a biopharmaceutical company that discovers, develops, manufactures, and markets an array of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi's R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has an operational presence in Europe, the Americas, Africa, Asia-Pacific, and the Middle East. Sanofi is headquartered in Paris, Ile-de-France, France.
Headquarters
France
Address
46 Avenue De La Grande Armee, Paris, Ile-de-France, 75017
Website
www.sanofi.com
Telephone
33 1 53774000
No of Employees
76,493
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SAN (EPA)
Revenue (2024)
$52.7B
5.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
40.5%
(2024 vs 2023)
Market Cap*
$105.2B
Net Profit Margin (2024)
XYZ
33.2%
(2024 vs 2023)
* As of and is in US$
Sanofi premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Specialty Care: | Aubagio |
| Eosinophilic Esophagitis | Cerezyme |
| Asthma | Cerdelga |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Divestiture | In June, the company sold its global business rights of Taxotere (docetaxel) to Boryung. |
| 2026 | Contracts/Agreements | In June, the company entered into a memorandum of understanding with the Department of Health – Abu Dhabi to promote the development of a Vaccine Innovation Centre in Abu Dhabi. |
| 2026 | Contracts/Agreements | In June, the company entered into a partnership with Snowflake to enhance its AI-powered drug development initiatives. |
Competitor Comparison
| Key Parameters | Sanofi | Johnson & Johnson | Eli Lilly and Co | Merck & Co Inc | Pfizer Inc |
|---|---|---|---|---|---|
| Headquarters | France | United States of America | United States of America | United States of America | United States of America |
| City | Paris | New Brunswick | Indianapolis | Rahway | New York City |
| State/Province | Ile-de-France | New Jersey | Indiana | New Jersey | New York |
| No. of Employees | 76,493 | 138,200 | 50,605 | 75,000 | 75,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Belen Garijo | Chief Executive Officer; Director | Executive Board | 2026 | - |
| Francois-Xavier Roger | Chief Financial Officer; Executive Vice President | Senior Management | 2024 | 64 |
| Natalie Bickford | Executive Vice President; Chief People Officer | Senior Management | 2020 | 56 |
| Emmanuel Frenehard | Executive Vice President; Chief Digital Officer | Senior Management | 2023 | 54 |
| Frederic Oudea | Chairman | Non Executive Board | 2023 | 63 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer